Cruxi
Compliance research
FDA’s acquired supplementary sheets explicitly connect 7-292 to 7-326 and state declaration-acceptance date(s) for the replaced recognition: recognition 7-292: 2026-12-20. Compare the exact edition and recognition limitations with your reports before agreeing the submission evidence or further work.
Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.
Exact FDA recognition records
Read these columns together. A complete recognition is not a device-specific testing instruction. The limitations are the FDA’s public metadata; the licensed standard itself is not reproduced.
| Recognition / edition | Public recognition limitations | Declaration transition context |
|---|---|---|
| FDA 7-292 CLSI M62 1st Edition Performance Standards for Susceptibility Testing of Mycobacteria Nocardia spp. and other Aerobic Actinomycetes | Partial Partial recognition. The following part(s) of the standard is (are) not recognized: Exceptions are noted on the FDA Antimicrobial Susceptibility Test Interpretive Criteria (STIC) (https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm575163.htm). In the absence of interpretive criteria and quality control parameters on this FDA webpage, consult the technical contacts below. [3] [6] | Exported transition expiration: 12/20/2026 |
| FDA 7-326 CLSI M24S 2nd Edition Performance Standards for Susceptibility Testing of Mycobacteria Nocardia spp. and Other Aerobic Actinomycetes | Partial Partial recognition. The following part(s) of the standard is (are) not recognized: Table 1. Broth Microdilution Breakpoints and Interpretive Categories for MTBC Tested in Middlebrook 7H9 Broth Supplemented With OADC Using MIC Panels Table 2. Susceptibility Testing of MTBC to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System Table 3. Antimicrobial Agents and Breakpoints for Testing MAC Table 4. Antimicrobial Agents and Breakpoints for Testing Mycobacterium kansasii Table 5. Antimicrobial Agents and Breakpoints for Testing Slowly Growing Nontuberculous Mycobacteria Other Than MAC and Mycobacterium kansasii Table 6. Antimicrobial Agents and Breakpoints for Testing Rapidly Growing Mycobacteria Table 7. Antimicrobial Agents and Breakpoints for Testing Nocardia spp. and Other Aerobic Actinomycetes Table 8. Expected Antimicrobial Susceptibility Patterns of the Most Commonly Isolated Nocardia spp Exceptions are noted on the FDA Antimicrobial Susceptibility Test Interpretive Criteria (STIC) (https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm575163.htm). In the absence of interpretive criteria and quality control parameters on this FDA webpage, consult the FDA technical contacts below. [2] [5] | No expiration date is stated in this acquired export row. That is not a guarantee of indefinite recognition. |
FDA recognition of CLSI M62 1st Edition [Rec# 7-292] will be superseded by recognition of CLSI M24S 2nd Edition [Rec# 7-326]. FDA will accept declarations of conformity, in support of premarket submissions, to [Rec# 7-292] until December 20, 2026. After this transition period, declarations of conformity to [Rec# 7-292] will not be accepted.
Exact statements were reconciled on both acquired sheets and against the old recognition’s exported date. [1] [4]
FDA public recognition metadata describes use of declarations of conformity in support of premarket submissions. A recognition transition is not a universal retesting deadline, a product ban, or proof that this standard applies to your device. The technical differences between licensed editions, adequacy of existing reports, buyer-specific route and final test scope remain incomplete. The comparison below does not reproduce the standard or establish FDA approval.
Method: Exact directed old-to-new statements are reconciled across both acquired sheets and the old export date. No name-similarity mapping or technical-clause inference.
Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.
Reconcile each report and declaration against CLSI M24S 2nd Edition and the replaced designation(s) CLSI M62 1st Edition. Record amendments and the exact report/device revision. A similar standard number is not an edition match.
Useful evidence: Report cover, method/edition references, amendments, declarations and device/configuration revision.
Use the complete FDA public limitation text in the comparison table. Map each listed exclusion, where present, to the relevant report sections and obtain a reasoned evidence assessment. Complete recognition still does not determine device applicability.
Useful evidence: Recognition-to-report coverage matrix, excluded-clause assessment and the licensed edition used by your specialist.
Record planned declaration/submission dates against the FDA sheet’s acceptance date(s): recognition 7-292: 2026-12-20. This concerns declarations supporting premarket submissions to the replaced recognition; do not treat it as a blanket deadline to retest or stop selling.
Useful evidence: Submission plan, intended declaration references, dated recognition-sheet check and rationale for the chosen evidence route.
Ask the specialist to assess the actual licensed edition/amendment differences for your design, materials, software and use environment. Separate a documented evidence gap from a changed title. This metadata comparison does not establish which tests changed or must be repeated.
Useful evidence: Edition gap assessment tied to the device and existing evidence, with a bridging rationale and unresolved inputs.
Request a report/recognition reconciliation and a justified gap assessment first. Separate any proposed additional evaluation or testing, samples, methods, deliverables and exclusions; agree them only after applicability and existing evidence are assessed.
Useful evidence: A scoped evidence-assessment quote; separately identified conditional work and report ownership.
Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.
Version not stated by the source · retrieved 2026-10-07
Source key D02 · snapshot 964988123dcdbd88b542cba6c3723a7baccbe7379ff92e06de44f0b9a8a51718
Version not stated by the source · retrieved 2026-10-07
Source key D02 · snapshot 94ccf56dc846c7f6d78d6ad77dc6e87d1803ac3612af01d6894949e34c4a78d8
Version not stated by the source · retrieved 2026-10-07
Source key D02 · snapshot 2c2825d37923537878a7e47327a2444d7eb1303fe9a0f55b9cf4af36ce6f74c7
Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.